Inmune Bio, Inc.

Finalize and submit a complete Marketing Authorisation Application to the UK MHRA for Ebstrocel

Deadline not yet reached (124 days left)

Announced: 21 Oct 2026
Due: 28 Feb 2027

Deadline
Met
Late
Not met
Today

What the company said

“Following MHRA feedback on the final pre-MAA package, INmune Bio plans to finalize and submit a complete application in February 2027”

SourceInmune Bio, Inc. Form 8-K press release, 2026-10-21
FilingSEC filing index
Deadline as statedin February 2027
Deadline used28 Feb 2027, the last day of the stated period
TypeRegulatory
Permanent referenceKI-C-2026-INMB-019861
Cite as https://keptindex.org/c/KI-C-2026-INMB-019861/ — this address never changes.

What we found

The deadline has not passed yet, so there is nothing to check. We look for evidence starting 30 days after 28 Feb 2027.

Commitment DNA

The structured record of this commitment. Fields the company did not state are left blank rather than guessed.

Event type: Regulatory submission
Indicative materiality: High rules
Action: Finalize
Deliverable: Complete UK MAA submission for Ebstrocel
Where: United Kingdom
Language: Expected (“expects”, “plans”)
In the company’s control: High
Specificity: High
Depends on: Regulatory

Tell me what happens

This deadline has not been settled yet. We check 30 days after it passes. Get an email when we record the outcome.

Alert me when this resolves

How this entry was checked

Commitment recordedThe company's words were matched word for word against the filing.
OutcomeNot yet assessed. Nothing is judged before the deadline.

Are you Inmune Bio, Inc.? You can publish an official statement next to this entry, free. Add a statement.

Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.

Report an error in this entry Reference: KI-C-2026-INMB-019861 · Corrections policy